New cell therapy targets Hard-to-Treat blood cancers in early trial
NCT ID NCT07574346
First seen May 08, 2026 · Last updated Jun 16, 2026 · Updated 4 times
Summary
This early-stage study tests a new treatment called IASO207 for people with certain types of B-cell blood cancers (like lymphoma) that have returned or not improved after standard therapy. The main goals are to check safety and find the right dose. About 18 adults aged 18 to 75 will take part. The treatment uses specially modified immune cells to attack the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.